New Delhi Cancer medicines could become significantly more affordable after the central government decided to cap trade margins on all non-scheduled drugs used in cancer treatment at 30% of the maximum retail price (MRP). The move could reduce the prices of some cancer medicines by up to 70%, offering substantial relief to patients facing high treatment costs.
According to sources, the new rule will apply uniformly to around 110 cancer medicines across categories, including branded, generic, domestic, imported, patented and non-patented drugs. The list includes 35 patented medicines. The order is expected to come into effect by the end of this month. The government aims to ease the financial burden on patients while ensuring that medicines remain consistently available in the market.
The decision targets excessive margins across the pharmaceutical distribution chain. However, the actual reduction in retail prices will depend on the existing price structure of individual medicines and how the new cap is implemented.
What Is a Trade Margin?
A trade margin is the difference between the price at which a pharmaceutical company sells a medicine to a distributor or stockist and the price ultimately paid by the patient. For example, if a company sells a medicine to a distributor for ₹100 and the retailer sells it to a patient for ₹500, the difference of ₹400 represents a 400% margin on the distributor price.
The government does not directly regulate the initial prices of non-scheduled medicines in the same way it regulates prices of scheduled formulations. Pharmaceutical companies may offer high trade margins to distributors and retailers to encourage the promotion and sale of particular brands.
By limiting these margins, the government intends to curb excessive mark-ups and make cancer medicines more affordable. The impact will depend on the existing margins and the final retail prices charged after the order takes effect.
Supreme Court Seeks Action Against Unethical Drug Marketing
In a separate development, the Supreme Court has taken a strict view of alleged unethical practices in which pharmaceutical companies provide expensive gifts, foreign trips and other benefits to doctors to encourage prescriptions of their branded medicines.
A bench of Justices Vikram Nath and Sandeep Mehta directed the central government to constitute a special committee to examine such practices. The committee will prepare recommendations for preventing improper pharmaceutical marketing and bringing companies’ promotional activities within a stronger regulatory framework.
The issue concerns allegations that certain companies use gifts, travel and other complimentary benefits to influence doctors’ prescribing decisions. Such practices have raised concerns about whether prescriptions are based primarily on patients’ medical needs or are influenced by commercial incentives.
The proposed committee is expected to suggest measures to curb unethical marketing and improve accountability in the pharmaceutical sector. The matter has come up at a time when the apex court is also examining a separate case relating to medicine prices and their affordable availability.
₹10,029 Crore in Penalties, 84% Still Unpaid
Despite regulatory action against companies found to have charged more than permitted prices for medicines, a substantial amount in penalties remains uncollected.
Data from the National Pharmaceutical Pricing Authority (NPPA) show that penalties totalling ₹10,029 crore had been imposed on pharmaceutical companies for overcharging on medicines up to March 31 this year. However, only ₹1,582.4 crore had been recovered. The outstanding amount stood at ₹8,447.4 crore, or approximately 84% of the total penalties imposed.
The figures raise questions about the effectiveness of enforcement and the recovery of money from companies accused of violating drug pricing rules. While penalties are intended to discourage overcharging and protect patients, the large outstanding amount highlights the challenges involved in recovering dues.
The data also point to cases of overcharging in different states. In Uttar Pradesh, cases involving hospitals charging prices 67% above the permitted level were reported, while Karnataka recorded cases involving overcharging of 52%.
Cipla and Other Major Companies Among Those Named
Company-wise records include significant amounts involving pharmaceutical companies such as Cipla, Johnson & Johnson, Ranbaxy, GlaxoSmithKline and Sun Pharma.
In one case involving Cipla’s salbutamol formulation, a penalty of ₹742.82 crore, including interest, was recorded. Of this amount, ₹93.96 crore had been recovered, leaving a substantial balance outstanding.
The cases underline the continuing challenge of ensuring compliance with drug pricing regulations and recovering amounts imposed for overcharging. For patients, high medicine costs can add considerably to the financial pressure of treatment, particularly in serious illnesses requiring prolonged medication.
The proposed cap on trade margins for cancer medicines, the Supreme Court’s move to examine unethical promotional practices and the outstanding penalties together highlight several aspects of pharmaceutical regulation: controlling distribution margins, preventing conflicts of interest in prescribing and enforcing price limits.
The effectiveness of these measures will depend on implementation, monitoring and the recovery of outstanding dues. For cancer patients, the immediate concern will be whether the new margin cap translates into lower prices at pharmacies and more affordable access to essential medicines.
